Hypothalamic glutamate levels following serotonergic stimulation: A pilot study using 7-Tesla magnetic resonance spectroscopy in healthy volunteers

Author(s):  
G.E. Jacobs ◽  
J. van der Grond ◽  
W.M. Teeuwisse ◽  
T.J.C. Langeveld ◽  
J. van Pelt ◽  
...  
Cancers ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 2598
Author(s):  
Lisa Maria Walchhofer ◽  
Ruth Steiger ◽  
Andreas Rietzler ◽  
Johannes Kerschbaumer ◽  
Christian Franz Freyschlag ◽  
...  

Background: Glioblastoma multiforme (GBM) is a highly malignant primary brain tumor with infiltration of, on conventional imaging, normal-appearing brain parenchyma. Phosphorus magnetic resonance spectroscopy (31P-MRS) enables the investigation of different energy and membrane metabolites. The aim of this study is to investigate regional differences of 31P-metabolites in GBM brains. Methods: In this study, we investigated 32 patients (13 female and 19 male; mean age 63 years) with naïve GBM using 31P-MRS and conventional MRI. Contrast-enhancing (CE), T2-hyperintense, adjacent and distant ipsilateral areas of the contralateral brain and the brains of age- and gender-matched healthy volunteers were assessed. Moreover, the 31P-MRS results were correlated with quantitative diffusion parameters. Results: Several metabolite ratios between the energy-dependent metabolites and/or the membrane metabolites differed significantly between the CE areas, the T2-hyperintense areas, the more distant areas, and even the brains of healthy volunteers. pH values and Mg2+ concentrations were highest in visible tumor areas and decreased with distance from them. These results are in accordance with the literature and correlated with quantitative diffusion parameters. Conclusions: This pilot study shows that 31P-MRS is feasible to show regional differences of energy and membrane metabolism in brains with naïve GBM, particularly between the different “normal-appearing” regions and between the contralateral hemisphere and healthy controls. Differences between various genetic mutations or clinical applicability for follow-up monitoring have to be assessed in a larger cohort.


2020 ◽  
Author(s):  
Gillian Macnaught ◽  
Olga Oikonomidou ◽  
Christopher T. Rodgers ◽  
William Clarke ◽  
Annette Cooper ◽  
...  

Abstract PURPOSETo explore the utility of phosphorus magnetic resonance spectroscopy (31P MRS) in identifying anthracycline-induced cardiac toxicity in patients with breast cancer.METHODS20 patients with newly diagnosed breast cancer receiving anthracycline-based chemotherapy had cardiac magnetic resonance assessment of left ventricular ejection fraction (LVEF) and 31P MRS to determine myocardial Phosphocreatine/Adenosine Triphosphate ratio (PCr/ATP) at three time points: pre, mid and end-chemotherapy. Plasma high sensitivity cardiac troponin-I (cTn-I) tests and electrocardiograms were also performed at these same time points. RESULTS PCr/ATP ratio did not change significantly between pre- and mid-chemo (2.16±0.46 v 2.00±0.56, p=0.80) and pre- and end-chemo (2.16±0.46 v 2.17±0.86, p=0.99). Mean LVEF reduced significantly by 5.1% between pre- and end-chemo (61.4±4.4 vs 56.3±8.1 %, p=0.02). Change in PCr/ATP ratios from pre- to end-chemo correlated inversely with changes in LVEF over the same period (r=-0.65, p=0.006). Plasma cTn-I increased progressively during chemotherapy from pre- to mid-chemo (1.35±0.81 to 4.40±2.64 ng/L; p=0.01) and from mid to end-chemo (4.40±2.64 to 18.33±13.23 ng/L; p=0.001). CONCLUSIONSIn this small cohort pilot study, we did not observe a clear change in mean PCr/ATP values during chemotherapy despite evidence of increased plasma cardiac biomarkers and reduced LVEF. Future similar studies should be adequately powered to take account of patient drop-out and variable changes in PCr/ATP.


2019 ◽  
Vol 10 ◽  
Author(s):  
Erin J. Meyer ◽  
Jeffrey N. Stout ◽  
Ai Wern Chung ◽  
P. Ellen Grant ◽  
Rebekah Mannix ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document